BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...
Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.
Fred Locke, MD, Moffitt Cancer Center, explains why this hematologic cancer is such an attractive target for chimeric antigen ...
T-cell lymphoma is a rare cancer that affects the lymphatic system. Learn about the types, signs, symptoms, treatments, and ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...
Some people believe that homeopathy can treat or even cure non-Hodgkin’s lymphoma (NHL). However, there is no evidence that this is true or that homeopathy can treat or cure any medical condition.
Pharmaceutical Technology on MSN18d
NICE green lights two blood cancer therapies for NHS useBMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
61%), transformed lymphoma (22%), high-grade B-cell lymphoma with MYC, BCL-2, and/or BCL-6 rearrangements (9%), primary mediastinal LBCL (4%), high-grade B-cell lymphoma NOS (3%), and grade 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback